# Salarius Pharmaceuticals Inc. (SLRX)

Source: https://www.quantisnow.com/company/SLRX
Generated: 2026-11-12T05:28:54.010Z

- Ticker: SLRX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2015
- Website: salariuspharma.com

## About

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.

## Latest SLRX news and filings

- 2026-01-09 22:08 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Salarius Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-salarius-pharmaceuticals-inc-6344737)
- 2026-01-08 17:38 UTC [SEC Form 8-K] [Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/salarius-pharmaceuticals-inc-filed-sec-form-8-k-amendments-to-articles-6342742)
- 2026-01-07 13:45 UTC [Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics](https://www.quantisnow.com/insight/salarius-pharmaceuticals-changes-corporate-name-to-decoy-therapeutics-and-nasdaq-6340478)
- 2026-01-02 22:14 UTC [SEC Form 8-K] [Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/salarius-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-6332576)
- 2026-01-02 22:13 UTC [SEC Form 4] [Director Hanish Arnold C sold $17 worth of shares (27 units at $0.64), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-hanish-arnold-c-sold-17-worth-of-shares-27-6332575)
- 2026-01-02 22:13 UTC [SEC Form 8-K] [SEC Form 8-K filed by Salarius Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-salarius-pharmaceuticals-inc-6332574)
- 2025-12-29 21:26 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Salarius Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-salarius-pharmaceuticals-inc-6328677)
- 2025-12-19 21:38 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Salarius Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-salarius-pharmaceuticals-inc-6324020)
- 2025-12-19 21:31 UTC [SEC Form 8-K] [Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/salarius-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-6323972)
- 2025-12-19 16:12 UTC [Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting](https://www.quantisnow.com/insight/salarius-pharmaceuticals-announces-adjournment-of-annual-meeting-information-for-reconvened-6323374)
- 2025-12-18 12:50 UTC [Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform](https://www.quantisnow.com/insight/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-6321247)
- 2025-12-01 13:00 UTC [Public Offering] [Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study](https://www.quantisnow.com/insight/salarius-pharmaceuticals-to-collaborate-with-texas-biomedical-research-institute-on-6296892)
- 2025-11-24 22:08 UTC [Insider Buy] [Director Hanish Arnold C bought $3,740 worth of shares (5,000 units at $0.75) (SEC Form 4)](https://www.quantisnow.com/insight/director-hanish-arnold-c-bought-3740-worth-of-shares-5000-6292191)
- 2025-11-20 21:42 UTC [Insider Buy] [Exec VP Finance, CFO Rosenblum Mark J bought $16,000 worth of shares (20,000 units at $0.80), increasing direct ownership by 11,299% to 20,177 units (SEC Form 4)](https://www.quantisnow.com/insight/exec-vp-finance-cfo-rosenblum-mark-j-bought-16000-worth-6289075)
- 2025-11-19 21:05 UTC [SEC Form 8-K] [Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/salarius-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-financial-6286882)
- 2025-11-19 19:42 UTC [Public Offering] [Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol "SLRX"](https://www.quantisnow.com/insight/salarius-pharmaceuticals-cites-errors-on-sp-capiq-platform-following-merger-6286732)
- 2025-11-18 16:53 UTC [SEC Form SCHEDULE 13G filed by Salarius Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-salarius-pharmaceuticals-inc-6284529)
- 2025-11-17 22:23 UTC [SEC Form 8-K] [Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/salarius-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-6283465)
- 2025-11-14 22:23 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Salarius Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-salarius-pharmaceuticals-inc-6281475)
- 2025-11-13 21:08 UTC [SEC Form 8-K] [Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/salarius-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-6277425)
- 2025-11-13 13:45 UTC [Public Offering] [Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger](https://www.quantisnow.com/insight/salarius-pharmaceuticals-and-decoy-therapeutics-complete-merger-6276452)
- 2025-11-12 16:00 UTC [Public Offering] [Strong Earnings and Biotech Resilience Define the Midweek Momentum](https://www.quantisnow.com/insight/strong-earnings-and-biotech-resilience-define-the-midweek-momentum-6273648)
- 2025-11-12 13:55 UTC [SEC Form 424B4 filed by Salarius Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b4-filed-by-salarius-pharmaceuticals-inc-6273251)
- 2025-11-11 14:18 UTC [Public Offering] [Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering](https://www.quantisnow.com/insight/salarius-pharmaceuticals-announces-pricing-of-7-million-underwritten-public-offering-6271997)
- 2025-11-10 21:00 UTC [SEC Form FWP] [SEC Form FWP filed by Salarius Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-fwp-filed-by-salarius-pharmaceuticals-inc-6270410)
- 2025-11-07 19:19 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Salarius Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-salarius-pharmaceuticals-inc-6267929)
- 2025-11-07 19:16 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Salarius Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-salarius-pharmaceuticals-inc-6267927)
- 2025-10-21 16:09 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by Salarius Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-salarius-pharmaceuticals-inc-6239857)
- 2025-10-21 15:57 UTC [SEC Form 8-K] [Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/salarius-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-6239837)
- 2025-10-14 12:00 UTC [SEC Form 8-K] [Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/salarius-pharmaceuticals-inc-filed-sec-form-8-k-other-events-financial-6231506)
- 2025-10-13 12:45 UTC [Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements](https://www.quantisnow.com/insight/salarius-pharmaceuticals-regains-compliance-with-all-nasdaq-listing-requirements-6230694)
- 2025-10-06 20:12 UTC [SEC Form 8-K] [Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/salarius-pharmaceuticals-inc-filed-sec-form-8-k-other-events-6224650)
- 2025-09-26 21:12 UTC [SEC Form FWP] [SEC Form FWP filed by Salarius Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-fwp-filed-by-salarius-pharmaceuticals-inc-6213331)
- 2025-09-23 21:27 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by Salarius Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-salarius-pharmaceuticals-inc-6209706)
- 2025-09-18 11:01 UTC [SEC Form 8-K] [Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/salarius-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-6204925)
- 2025-09-09 12:04 UTC [SEC Form 8-K] [Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/salarius-pharmaceuticals-inc-filed-sec-form-8-k-other-events-financial-6194393)
- 2025-09-09 12:00 UTC [Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement](https://www.quantisnow.com/insight/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-6194297)
- 2025-08-27 20:10 UTC [SEC Form 8-K] [Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/salarius-pharmaceuticals-inc-filed-sec-form-8-k-other-events-6180826)
- 2025-08-26 21:29 UTC [SEC Form 8-K] [Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/salarius-pharmaceuticals-inc-filed-sec-form-8-k-other-events-financial-6179613)
- 2025-08-26 20:07 UTC [SEC Form 8-K] [Amendment: Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-salarius-pharmaceuticals-inc-filed-sec-form-8-k-financial-statements-6179188)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SLRX
- Earnings history: https://www.quantisnow.com/earnings/SLRX
- Dividend history: https://www.quantisnow.com/dividends/SLRX
- Insider transactions: https://www.quantisnow.com/insiders/SLRX
- Options chain: https://www.quantisnow.com/options/SLRX
- SEC 8-K filings only: https://www.quantisnow.com/company/SLRX/8-k
- RSS and alerts for SLRX: https://www.quantisnow.com/docs/rss-feeds.md